User profiles for Jordi Rodon

Jordi Rodon

- Verified email at mdanderson.org - Cited by 18852

Jordi Rodon

- Verified email at irta.cat - Cited by 1059

Detection of SARS-CoV-2 in a cat owned by a COVID-19− affected patient in Spain

J Segalés, M Puig, J Rodon… - Proceedings of the …, 2020 - National Acad Sciences
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of
COVID-19, is considered a zoonotic pathogen mainly transmitted human to human. Few …

Development of PI3K inhibitors: lessons learned from early clinical trials

J Rodon, R Dienstmann, V Serra… - Nature reviews Clinical …, 2013 - nature.com
The phosphatidylinositol 3-kinase (PI3K) pathway has an important role in cell metabolism,
growth, migration, survival and angiogenesis. Drug development aimed at targetable genetic …

[PDF][PDF] Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

JC Bendell, J Rodon, HA Burris, M De Jonge… - J Clin …, 2012 - researchgate.net
… Bendell, Jordi Rodon, Howard A. Burris, Maja de Jonge, Jaap Verweij, Diana Birle, David
Demanse, Stefan S. De Buck, Qinhua C. … Burris, Sarah Cannon Research Institute …

[HTML][HTML] Analytical and clinical performance of the panbio COVID-19 antigen-detecting rapid diagnostic test

…, J Vergara-Alert, J Rodon… - The Journal of …, 2021 - ncbi.nlm.nih.gov
We read with interest the recent article by Collins et al. 1 regarding under-identification of
hospital clusters of Group B Streptococcus (GBS) disease outbreaks. The first step in …

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

J Rodon, JC Soria, R Berger, WH Miller, E Rubin… - Nature medicine, 2019 - nature.com
Precision medicine focuses on DNA abnormalities, but not all tumors have tractable genomic
alterations. The WINTHER trial ( NCT01856296 ) navigated patients to therapy on the basis …

Actively personalized vaccination trial for newly diagnosed glioblastoma

…, M Skardelly, D Migliorini, JR Kroep, M Idorn, J Rodon… - Nature, 2019 - nature.com
Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in
cancer treatment that use checkpoint inhibitors 1 , 2 . For treatments using checkpoint …

[PDF][PDF] TGF-β receptor inhibitors target the CD44high/Id1high glioma-initiating cell population in human glioblastoma

J Anido, A Sáez-Borderías, A Gonzàlez-Juncà… - Cancer cell, 2010 - cell.com
Glioma-initiating cells (GICs), also called glioma stem cells, are responsible for tumor initiation,
relapse, and therapeutic resistance. Here, we show that TGF-β inhibitors, currently under …

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

…, V Peg, S Ramon y Cajal, J Carles, J Rodon… - Nature …, 2015 - nature.com
Cell-free circulating tumour DNA (ctDNA) in plasma has been shown to be informative of the
genomic alterations present in tumours and has been used to monitor tumour progression …

HER kinase inhibition in patients with HER2-and HER3-mutant cancers

DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura… - Nature, 2018 - nature.com
Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively)
are found in a wide range of cancers. Preclinical modelling suggests that a subset of these …

A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors

J Rodon, HA Tawbi, AL Thomas, RG Stoller… - Clinical cancer …, 2014 - AACR
Purpose: This phase I trial was undertaken to determine the maximum tolerated dose (MTD),
dose-limiting toxicities (DLT), safety, tolerability, pharmacokinetics, pharmacodynamics, …